Literature DB >> 33417072

γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology.

Melanie A Felmlee1, Bridget L Morse2, Marilyn E Morris3.   

Abstract

Gamma-hydroxybutyrate (GHB) is a short-chain fatty acid present endogenously in the brain and used therapeutically for the treatment of narcolepsy, as sodium oxybate, and for alcohol abuse/withdrawal. GHB is better known however as a drug of abuse and is commonly referred to as the "date-rape drug"; current use in popular culture includes recreational "chemsex," due to its properties of euphoria, loss of inhibition, amnesia, and drowsiness. Due to the steep concentration-effect curve for GHB, overdoses occur commonly and symptoms include sedation, respiratory depression, coma, and death. GHB binds to both GHB and GABAB receptors in the brain, with pharmacological/toxicological effects mainly due to GABAB agonist effects. The pharmacokinetics of GHB are complex and include nonlinear absorption, metabolism, tissue uptake, and renal elimination processes. GHB is a substrate for monocarboxylate transporters, including both sodium-dependent transporters (SMCT1, 2; SLC5A8; SLC5A12) and proton-dependent transporters (MCT1-4; SLC16A1, 7, 8, and 3), which represent significant determinants of absorption, renal reabsorption, and brain and tissue uptake. This review will provide current information of the pharmacology, therapeutic effects, and pharmacokinetics/pharmacodynamics of GHB, as well as therapeutic strategies for the treatment of overdoses. Graphical abstract.

Entities:  

Keywords:  GABAB receptors addiction; monocarboxylate transporters; narcolepsy; overdose treatment strategies; pharmacology; toxicity

Mesh:

Substances:

Year:  2021        PMID: 33417072      PMCID: PMC8098080          DOI: 10.1208/s12248-020-00543-z

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  134 in total

Review 1.  SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers.

Authors:  Marilyn E Morris; Vivian Rodriguez-Cruz; Melanie A Felmlee
Journal:  AAPS J       Date:  2017-06-29       Impact factor: 4.009

Review 2.  A brief overview of the clinical pharmacology of "club drugs".

Authors:  Gena Covell Britt; Elinore F McCance-Katz
Journal:  Subst Use Misuse       Date:  2005       Impact factor: 2.164

3.  γ-Hydroxybutyrate blood/plasma partitioning: effect of physiologic pH on transport by monocarboxylate transporters.

Authors:  Bridget L Morse; Melanie A Felmlee; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2011-10-05       Impact factor: 3.922

4.  Treatment of γ-Hydroxybutyric Acid and γ-Butyrolactone Overdose with Two Potent Monocarboxylate Transporter 1 Inhibitors, AZD3965 and AR-C155858.

Authors:  Kristin E Follman; Marilyn E Morris
Journal:  J Pharmacol Exp Ther       Date:  2019-04-22       Impact factor: 4.030

5.  In vivo conversion of gamma-aminobutyric acid and 1,4-butanediol to gamma-hydroxybutyric acid in rat brain. Studies using stable isotopes.

Authors:  O C Snead; R Furner; C C Liu
Journal:  Biochem Pharmacol       Date:  1989-12-15       Impact factor: 5.858

6.  Expression of the sodium-coupled monocarboxylate transporters SMCT1 (SLC5A8) and SMCT2 (SLC5A12) in retina.

Authors:  Pamela M Martin; Ying Dun; Barbara Mysona; Sudha Ananth; Penny Roon; Sylvia B Smith; Vadivel Ganapathy
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-07       Impact factor: 4.799

7.  Effects of monocarboxylate transporter inhibition on the oral toxicokinetics/toxicodynamics of γ-hydroxybutyrate and γ-butyrolactone.

Authors:  Bridget L Morse; Marilyn E Morris
Journal:  J Pharmacol Exp Ther       Date:  2013-02-07       Impact factor: 4.030

Review 8.  Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level.

Authors:  Wim van den Brink; Giovanni Addolorato; Henri-Jean Aubin; Amine Benyamina; Fabio Caputo; Maurice Dematteis; Antoni Gual; Otto-Michael Lesch; Karl Mann; Icro Maremmani; David Nutt; François Paille; Pascal Perney; Jürgen Rehm; Michel Reynaud; Nicolas Simon; Bo Söderpalm; Wolfgang H Sommer; Henriette Walter; Rainer Spanagel
Journal:  Addict Biol       Date:  2018-07       Impact factor: 4.280

9.  Presentations to an urban emergency department in Switzerland due to acute γ-hydroxybutyrate toxicity.

Authors:  Evangelia Liakoni; Fabio Walther; Christian H Nickel; Matthias E Liechti
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2016-08-31       Impact factor: 2.953

10.  Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport.

Authors:  Becky M Bola; Amy L Chadwick; Filippos Michopoulos; Kathryn G Blount; Brian A Telfer; Kaye J Williams; Paul D Smith; Susan E Critchlow; Ian J Stratford
Journal:  Mol Cancer Ther       Date:  2014-10-03       Impact factor: 6.261

View more
  6 in total

Review 1.  Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse.

Authors:  Emma Tay; Wing Kwan Winky Lo; Bridin Murnion
Journal:  Subst Abuse Rehabil       Date:  2022-02-09

Review 2.  Gut-Lung Microbiota in Chronic Pulmonary Diseases: Evolution, Pathogenesis, and Therapeutics.

Authors:  Chang Yi Shi; Chen Huan Yu; Wen Ying Yu; Hua Zhong Ying
Journal:  Can J Infect Dis Med Microbiol       Date:  2021-12-03       Impact factor: 2.471

Review 3.  Toxicological Characterization of GHB as a Performance-Enhancing Drug.

Authors:  Arianna Giorgetti; Francesco Paolo Busardò; Raffaele Giorgetti
Journal:  Front Psychiatry       Date:  2022-04-18       Impact factor: 5.435

Review 4.  Increased/Targeted Brain (Pro)Drug Delivery via Utilization of Solute Carriers (SLCs).

Authors:  Johanna Huttunen; Santosh Kumar Adla; Magdalena Markowicz-Piasecka; Kristiina M Huttunen
Journal:  Pharmaceutics       Date:  2022-06-10       Impact factor: 6.525

5.  Easy and convenient millimole-scale synthesis of new, potential biomarkers for gamma-hydroxybutyric acid (GHB) intake: Feasible for analytical laboratories.

Authors:  Christian Steuer; Dario Quattrini; Justine Raeber; Philipp Waser; Andrea E Steuer
Journal:  Drug Test Anal       Date:  2022-04-21       Impact factor: 3.234

6.  Pharmacokinetics, bioavailability, and bioequivalence of lower-sodium oxybate in healthy participants in two open-label, randomized, crossover studies.

Authors:  Cuiping Chen; Jack Jenkins; Katie Zomorodi; Roman Skowronski
Journal:  Clin Transl Sci       Date:  2021-06-25       Impact factor: 4.689

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.